Free Trial

iTeos Therapeutics (ITOS) Competitors

iTeos Therapeutics logo
$10.07 -0.11 (-1.08%)
As of 04:00 PM Eastern

ITOS vs. SDGR, EVO, OCUL, VERA, ETNB, BHVN, ANIP, MESO, EWTX, and JANX

Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Schrodinger (SDGR), Evotec (EVO), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), 89BIO (ETNB), Biohaven (BHVN), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.

iTeos Therapeutics vs. Its Competitors

iTeos Therapeutics (NASDAQ:ITOS) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

iTeos Therapeutics presently has a consensus target price of $15.86, suggesting a potential upside of 57.47%. Schrodinger has a consensus target price of $33.25, suggesting a potential upside of 61.17%. Given Schrodinger's stronger consensus rating and higher probable upside, analysts plainly believe Schrodinger is more favorable than iTeos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iTeos Therapeutics
0 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.14
Schrodinger
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

iTeos Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

In the previous week, Schrodinger had 6 more articles in the media than iTeos Therapeutics. MarketBeat recorded 9 mentions for Schrodinger and 3 mentions for iTeos Therapeutics. Schrodinger's average media sentiment score of 0.39 beat iTeos Therapeutics' score of 0.34 indicating that Schrodinger is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iTeos Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Schrodinger
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

iTeos Therapeutics has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iTeos Therapeutics$35M11.01-$134.41M-$3.04-3.31
Schrodinger$207.54M7.29-$187.12M-$2.63-7.84

97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

iTeos Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -83.39%. iTeos Therapeutics' return on equity of -21.37% beat Schrodinger's return on equity.

Company Net Margins Return on Equity Return on Assets
iTeos TherapeuticsN/A -21.37% -18.55%
Schrodinger -83.39%-44.74%-26.29%

Summary

iTeos Therapeutics and Schrodinger tied by winning 8 of the 16 factors compared between the two stocks.

Get iTeos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ITOS vs. The Competition

MetriciTeos TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$389.63M$2.92B$5.53B$9.03B
Dividend YieldN/A2.44%5.24%4.02%
P/E Ratio-3.3120.3027.1920.03
Price / Sales11.01277.89423.15112.84
Price / CashN/A41.7026.2128.59
Price / Book0.627.397.925.55
Net Income-$134.41M-$55.04M$3.17B$248.49M
7 Day Performance1.00%3.01%2.18%5.37%
1 Month Performance-0.98%-0.21%1.25%6.63%
1 Year Performance-28.15%4.48%33.90%21.20%

iTeos Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ITOS
iTeos Therapeutics
3.1455 of 5 stars
$10.07
-1.1%
$15.86
+57.5%
-27.4%$389.63M$35M-3.3190
SDGR
Schrodinger
2.8034 of 5 stars
$20.12
-2.4%
$32.80
+63.0%
+1.2%$1.51B$207.54M-7.65790High Trading Volume
EVO
Evotec
1.669 of 5 stars
$4.20
+1.0%
$5.93
+41.3%
-20.8%$1.48B$862.40M0.004,827Positive News
OCUL
Ocular Therapeutix
3.9175 of 5 stars
$9.28
+0.7%
$17.33
+86.8%
+40.3%$1.47B$63.72M-8.07230Positive News
VERA
Vera Therapeutics
3.3346 of 5 stars
$23.56
+4.0%
$65.00
+175.9%
-33.4%$1.44BN/A-7.8540Positive News
ETNB
89BIO
1.5516 of 5 stars
$9.82
-0.4%
$26.43
+169.1%
+34.8%$1.44BN/A-2.9140
BHVN
Biohaven
3.1537 of 5 stars
$14.11
+0.1%
$58.46
+314.3%
-57.1%$1.44BN/A-1.51239
ANIP
ANI Pharmaceuticals
3.6244 of 5 stars
$65.25
-0.4%
$80.13
+22.8%
+6.3%$1.42B$614.38M-51.38600
MESO
Mesoblast
2.1124 of 5 stars
$10.89
-0.3%
$18.00
+65.3%
+39.4%$1.40B$5.90M0.0080
EWTX
Edgewise Therapeutics
2.6289 of 5 stars
$13.11
-0.5%
$40.00
+205.1%
-33.3%$1.39BN/A-8.4660
JANX
Janux Therapeutics
2.0216 of 5 stars
$23.10
-0.2%
$95.25
+312.3%
-38.5%$1.37B$10.59M-16.9930

Related Companies and Tools


This page (NASDAQ:ITOS) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners